Alkermes plc. Finite-Lived Intangible Assets, Amortization Expense (Deprecated 2012-01-31)
Alkermes plc. (ALKS) reported Finite-Lived Intangible Assets, Amortization Expense (Deprecated 2012-01-31) of $10.40 million for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-07-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpense · last filed 2012-07-26
- Alkermes plc. finite-lived intangible assets, amortization expense (deprecated 2012-01-31) for the quarter ending 2012-06-30 was $10.40M.
- Alkermes plc. finite-lived intangible assets, amortization expense (deprecated 2012-01-31) for fiscal 2012 was $25.40M.
| Period end | Finite-Lived Intangible Assets, Amortization Expense (Deprecated 2012-01-31) 3 month | Finite-Lived Intangible Assets, Amortization Expense (Deprecated 2012-01-31) 12 month |
|---|---|---|
| 2012-06-30 | $10.40M 10-Q · filed 2012-07-26 | |
| 2012-03-31 | $25.40M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |